Cervical Cancer Prevention: HPV Vaccines, Pap Smears, and Early Detection

Understanding Cervical Cancer and Its Causes

Cervical cancer is a malignancy that develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. It is one of the most preventable and—when caught early—one of the most treatable forms of cancer. Globally, cervical cancer remains the fourth most common cancer in women, though its incidence and mortality have declined dramatically in countries with access to screening programs and HPV vaccination. Understanding the cause of cervical cancer is the first step toward understanding why prevention is so effective.

The overwhelming majority of cervical cancers—approximately 99 percent—are caused by persistent infection with certain strains of the human papillomavirus (HPV). HPV is the most common sexually transmitted infection in the United States and worldwide; the Centers for Disease Control and Prevention (CDC) estimates that nearly all sexually active people will be infected with HPV at some point in their lives. Most HPV infections are cleared by the immune system within one to two years without causing any symptoms or lasting harm. However, when certain high-risk strains of HPV—particularly HPV types 16 and 18—persist in the cervical cells, they can cause cellular changes that, over years to decades, may progress to precancerous lesions and ultimately to invasive cervical cancer.

There are over 200 strains of HPV, of which about 40 can be sexually transmitted. The high-risk strains associated with cervical cancer (as well as other cancers including oropharyngeal, anal, vulvar, vaginal, and penile cancers) are distinct from the low-risk strains that cause genital warts. Infection with high-risk HPV strains does not produce symptoms and cannot be felt; the only way to know whether HPV is present is through testing. This is one reason why regular cervical cancer screening—which can detect both HPV infection and the cellular changes HPV may cause—is so important, as women cannot rely on symptoms to alert them to early problems.

The HPV Vaccine: Protection Before Exposure

The development of HPV vaccines represents one of the most significant advances in cancer prevention in modern medicine. Currently approved in the United States is Gardasil 9, a vaccine that protects against nine strains of HPV: the two high-risk strains most responsible for cervical cancer (HPV 16 and 18), five additional high-risk strains (31, 33, 45, 52, and 58), and two low-risk strains that cause genital warts (6 and 11). Together, these nine strains account for approximately 90 percent of cervical cancers, making the vaccine extraordinarily effective at preventing the most dangerous HPV infections.

The CDC's Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination for all preteens—both boys and girls—at age 11 or 12, with the series of two shots given at least six months apart. The vaccine is recommended at this age because it is most effective when given before any potential exposure to HPV, meaning before the onset of sexual activity. The immune response to the vaccine is also strongest in preteens. Vaccination is also recommended through age 26 for anyone who was not adequately vaccinated as a preteen, and for some adults ages 27 to 45 who have not been vaccinated and who are at risk for new HPV infection, based on shared clinical decision-making with their healthcare provider.

The HPV vaccines have an exceptional safety record, having been studied in clinical trials involving tens of thousands of participants and monitored in post-market surveillance covering hundreds of millions of doses administered worldwide. The most common side effects are mild and temporary: pain, redness, and swelling at the injection site, and occasionally dizziness or fainting (which is common with many vaccines and can be prevented by having the recipient sit or lie down for 15 minutes after vaccination). Extensive studies have found no credible evidence linking HPV vaccination to serious adverse events, and major health organizations around the world have consistently affirmed the vaccine's safety and efficacy. Despite this evidence, vaccine hesitancy has limited uptake in some populations, contributing to ongoing preventable cervical cancers.

Pap Smear Screening: What It Is and Why It Matters

The Pap smear (or Pap test), named after the physician Georgios Papanicolaou who developed the technique in the 1940s, is a cervical cancer screening test that examines cells collected from the cervix under a microscope for abnormal changes. The Pap smear cannot diagnose cervical cancer directly; rather, it detects cellular changes—ranging from mild abnormalities to severe precancerous lesions—that may indicate the presence of cancer or an elevated risk of developing it. When precancerous changes are detected and treated, cancer can be prevented; when early-stage cancer is detected, it can be treated with high success rates. The introduction of widespread Pap smear screening has been one of the primary reasons for the dramatic decline in cervical cancer deaths in developed countries over the past 60 years.

A Pap smear is performed during a pelvic exam. The healthcare provider uses a speculum to visualize the cervix and then uses a small brush or spatula to collect cells from the cervix and the endocervical canal. The collected cells are sent to a laboratory, where a pathologist or cytotechnologist examines them under a microscope and classifies any abnormalities according to standardized criteria. The procedure is quick—typically taking only a few minutes—and most women experience little to no discomfort, though mild cramping or spotting afterward is normal. For the most accurate results, it is recommended that women avoid having sex, using tampons, douching, or using vaginal medications or spermicides for two days before the test.

The accuracy of Pap smear screening is enhanced by co-testing with an HPV DNA test, which detects the presence of high-risk HPV strains in cervical cells. Co-testing can identify women who have HPV infection before cellular changes are visible under the microscope, allowing for earlier surveillance and intervention. In recent years, primary HPV testing—using the HPV test alone as the first-line screening test and following up with a Pap smear only when HPV is detected—has gained acceptance as an alternative approach that some studies suggest may be more sensitive than Pap testing alone.

Screening Guidelines: How Often Should You Be Screened?

Current U.S. cervical cancer screening guidelines, developed by the American Cancer Society (ACS), the U.S. Preventive Services Task Force (USPSTF), and the American College of Obstetricians and Gynecologists (ACOG), have evolved in recent years to reflect new evidence about the natural history of HPV infection and the effectiveness of different screening approaches. The guidelines aim to balance the benefits of early detection against the harms of over-screening, which can lead to unnecessary procedures, anxiety, and potential complications.

For women aged 21 to 65, the current guidelines generally recommend: Pap testing alone every three years (ages 21–29); starting at age 30, either Pap testing alone every three years, or co-testing with both a Pap smear and an HPV test every five years, or HPV testing alone every five years. Screening is not recommended for women under 21 regardless of sexual activity, because HPV infections in teenagers and young adults are almost always cleared by the immune system. Screening can be discontinued in women over 65 who have had adequate prior screening with normal results, though women with certain risk factors—including HIV infection, a history of cervical cancer, or prior abnormal screening results—may need different screening schedules. Women who have had a hysterectomy with removal of the cervix for non-cancer reasons generally do not need continued cervical cancer screening.

It is important to understand that the screening intervals have lengthened in recent years not because cervical cancer screening is less important, but because evidence shows that longer intervals are safe and effective when the recommended tests are used. Women who have concerns about their individual screening needs should discuss them with their healthcare provider, taking into account personal risk factors, preferences, and the specific guidelines applicable to their situation. Following the recommended schedule consistently is more important than the specific interval chosen, and women who have never been screened or who are overdue for screening should seek it promptly.

Understanding Abnormal Results: CIN and HSIL

Receiving abnormal cervical cancer screening results can be anxiety-provoking, but it is important to understand that most abnormal results do not indicate cancer. The most common abnormal Pap smear findings are described using the Bethesda System, which uses standardized terminology to classify the degree of cellular abnormality. Results range from ASC-US (atypical squamous cells of undetermined significance—the mildest abnormality) through LSIL (low-grade squamous intraepithelial lesion) and HSIL (high-grade squamous intraepithelial lesion) to the most serious categories that may indicate cancer.

When a Pap smear returns an abnormal result, the next step typically depends on the degree of abnormality and the patient's HPV status. Mild abnormalities (ASC-US) in women who test negative for high-risk HPV may simply require more frequent surveillance. More significant abnormalities or positive HPV results typically lead to colposcopy—a procedure in which a healthcare provider examines the cervix with a magnifying instrument called a colposcope and may take small biopsies of any suspicious areas. Biopsies allow pathologists to grade the degree of cellular abnormality on a scale called cervical intraepithelial neoplasia (CIN 1, 2, or 3), with CIN 3 being the most severe precancerous change.

The management of precancerous cervical changes depends on the grade of abnormality, the patient's age and reproductive plans, and other clinical factors. Mild dysplasia (CIN 1) is often monitored rather than treated, as many cases resolve spontaneously. More severe dysplasia (CIN 2 and 3) is typically treated to prevent progression to cancer. Treatment options include loop electrosurgical excision procedure (LEEP), which uses a thin wire loop to remove abnormal tissue, and cryotherapy or laser therapy to destroy abnormal cells. These procedures are generally performed in an outpatient setting, have high success rates, and can usually preserve fertility. Follow-up after treatment is essential, as treated women remain at elevated risk for recurrence and should follow their provider's recommendations for ongoing surveillance.

Barriers to Prevention and Disparities in Outcomes

Despite the availability of highly effective prevention and early detection tools, cervical cancer continues to disproportionately affect women who face barriers to accessing healthcare. Racial and ethnic disparities in cervical cancer incidence and mortality are substantial and well-documented. Black women and Hispanic women have higher rates of cervical cancer diagnosis and death than white women in the United States, reflecting disparities in access to screening and vaccination, barriers related to language and cultural factors, and the broader social determinants of health that affect preventive care utilization.

Women in rural areas face access barriers including geographic distance from healthcare providers, shortage of gynecologists and primary care physicians, and limited public health infrastructure for vaccination programs. Women without health insurance or with inadequate coverage may delay or forgo screening due to cost. Low-income women enrolled in Medicaid may face provider availability challenges. The CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides free or low-cost Pap smears and other services to low-income, uninsured, or underinsured women, and advocacy organizations work to improve access to these resources.

Globally, the disparities are even more dramatic. The vast majority of cervical cancer deaths—over 85 percent—occur in low- and middle-income countries that lack robust vaccination programs and screening infrastructure. The World Health Organization has launched a global initiative to eliminate cervical cancer as a public health problem, with targets for HPV vaccination coverage, screening rates, and treatment access. Meeting these targets would require unprecedented investment in healthcare infrastructure and capacity in the world's poorest countries, but the goal is achievable given that the tools needed—safe and effective vaccines and simple screening tests—already exist. Ensuring that every woman in the world has access to these tools is one of the most important public health challenges of our time.